Compare · BIIB vs TWST
BIIB vs TWST
Side-by-side comparison of Biogen Inc. (BIIB) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.84B, about 6.7x TWST ($4.31B).
- Over the past year, BIIB is up 43.6% and TWST is up 109.9% - TWST leads by 66.3 points.
- TWST has been more active in the news (14 items in the past 4 weeks vs 9 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 13 for TWST).
- Company
- Biogen Inc.
- Twist Bioscience Corporation
- Price
- $192.65-1.36%
- $70.04+1.35%
- Market cap
- $28.84B
- $4.31B
- 1M return
- +0.68%
- +19.68%
- 1Y return
- +43.59%
- +109.89%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 14
- Recent ratings
- 25
- 13
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest BIIB
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
- BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
- Evercore ISI resumed coverage on Biogen
Latest TWST
- Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)
- Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)
- Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)
- Chief Executive Officer Leproust Emily M. exercised 16,470 shares at a strike of $8.82 and sold $1,118,555 worth of shares (16,470 units at $67.91) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Accounting Officer Werner Robert F. sold $49,987 worth of shares (800 units at $62.48), decreasing direct ownership by 2% to 48,186 units (SEC Form 4) (tax liability)
- Chief Executive Officer Leproust Emily M. exercised 49,299 shares at a strike of $8.82 and sold $3,213,653 worth of shares (49,299 units at $65.19) as part of a pre-agreed trading plan (SEC Form 4)
- Director Starovasnik Melissa A. sold $30,520 worth of shares (500 units at $61.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,722 units (SEC Form 4)
- Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
- SVP of Human Resources Green Paula sold $74,507 worth of shares (1,399 units at $53.26), decreasing direct ownership by 1% to 121,589 units (SEC Form 4) (for tax liability)
- President and COO Finn Patrick John sold $221,549 worth of shares (4,160 units at $53.26), decreasing direct ownership by 1% to 274,804 units (SEC Form 4) (withholding obligation)